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The escalating global prevalence of arboviral diseases emphasizes the need to improve our
understanding of their biology. Research in this area has been hindered by the lack of
molecular tools for studying virus-mosquito interactions. Here, we develop an Aedes aegypti
cell line which stably expresses Zika virus (ZIKV) capsid proteins in order to study virus-
vector protein-protein interactions through quantitative label-free proteomics. We identify
157 interactors and show that eight have potentially pro-viral activity during ZIKV infection in
mosquito cells. Notably, silencing of transitional endoplasmic reticulum protein TER94 pre-
vents ZIKV capsid degradation and significantly reduces viral replication. Similar results are
observed if the TER94 ortholog (VCP) functioning is blocked with inhibitors in human cells. In
addition, we show that an E3 ubiquitin-protein ligase, UBR5, mediates the interaction
between TER94 and ZIKV capsid. Our study demonstrates a pro-viral function for TER94/
VCP during ZIKV infection that is conserved between human and mosquito cells.
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Zika virus (ZIKV) is an arbovirus of the Flaviviridaefamily1–4 originally isolated from a Rhesus monkey inUganda in 19475,6. Though previously limited to Africa
and Southeast Asia, outbreaks across Pacific Ocean islands were
detected throughout 2013–20147,8. During the recent outbreak in
South and Central America in 2015–2016, the yellow fever
mosquito (Aedes aegypti) was identified as the key ZIKV
vector9–12. ZIKV infection is associated with mild and unspecific
disease manifestations but has also been linked to serious com-
plications including Guillain-Barré syndrome and congenital Zika
syndrome13–19. Currently no drugs or vaccines against ZIKV are
available, which enforces the need for complementary vector
research in mosquito cells to better understand its replication,
transmission, and interaction with cellular proteins20,21.
The ZIKV RNA genome is translated into a single polyprotein
processed by host and viral proteases into structural and non-
structural proteins22–24. ZIKV enters cells via receptor-mediated
endocytosis25 and is trafficked in endosomes where lowering the
pH induces membrane fusion26, exposing the nucleocapsid to the
cytoplasm for uncoating. However, nucleocapsid disassembly is
less well understood27,28. There are two forms of ZIKV capsid
proteins in infected cells (Fig. 1a). Initially, anchored capsid (AC;
122 amino acids) is bound to the endoplasmic reticulum (ER)
membrane by its trans-membrane helices. During viral replica-
tion, AC is cleaved by viral proteases, releasing an untethered
capsid (C; 104 amino acids) that assembles with the RNA gen-
ome for release23,29,30. Despite its small size, protein–protein
interaction (PPI) studies have shown that ZIKV capsid interacts
with several human cellular pathways and affects intracellular
functions during viral replication31,32. These PPI studies in
mammalian systems33–42 have been pivotal in understanding
ZIKV biology43. However, PPIs are largely unexplored in mos-
quito cells due to the lack of molecular tools required for such
studies.
Here, we identify protein interactors of ZIKV anchored and
untethered capsid in Ae. aegypti cells by developing AF5 stable
cell lines expressing ZIKV capsid proteins, allowing mass
spectrometry-based experiments to be carried out. We identified
157 potential interactors, with 38 shared between C and AC. A
knockdown screen of 24 shared interactors showed that eight
were pro-viral host factors. This set of pro-viral interactors
included transitional endoplasmic reticulum 94 (TER94), whose
human ortholog is valosin-containing protein (VCP/p97). TER94
functions with a number of co-factors to segregate target proteins
from protein assemblies following the ubiquitin-proteasome
pathway (UPP)44–47. Our results suggest that TER94 targets
ZIKV capsid for proteasomal degradation in AF5 cells. We found
that this role is conserved between mosquito and human cells and
that TER94/VCP is needed during the early stages of infection.
We also identified a potential co-factor, ubiquitin protein ligase
E3 component N-recognin 5 (UBR5), involved in mediating
TER94/VCP-ZIKV capsid interactions in mosquito and human
cells. These results suggest that TER94/VCP plays an important
role in viral RNA uncoating by interacting with ZIKV capsid and
subsequently trafficking it for proteasomal degradation. This
study increases our understanding of ZIKV capsid functions and
opens a door to pursue further PPI studies in mosquito cells.
These studies will be required to understand the commonalities
and differences between arboviral interactions with host proteins
in vector and mammalian cells.
Results
Developing stable mosquito cell lines to study ZIKV capsid-Ae.
aegypti PPI. To study the ZIKV capsid interactome in mosquito
cells, AF5 cells stably expressing ZIKV C or AC proteins were
developed. Coding sequences for C or AC from a ZIKV infectious
cDNA (icDNA) clone, pCCI-SP6-ZIKV48 were cloned into an
expression plasmid under the control of an Ae. aegypti poly-
ubiquitin (PUb) promoter49, with a Zeocin resistance gene
(ZeoR) separated from V5-tagged C or AC by two copies of 2A
autoprotease (Fig. 1a). Plasmids were linearized and transfected
into AF5 cells followed by ZeoR selection to obtain stable cell
lines. Immunostaining of AF5-V5-AC and AF5-V5-C cells
revealed capsid localization along the perinuclear region, with
V5-C appearing to be more dispersed, while minimal speckling of
V5-AC was observed (Supplementary Fig. 1a).
The pipeline for studying ZIKV capsid interactome in stable
mosquito cell lines is straightforward and can be easily adapted to
other viral proteins (Fig. 1b). This system involves immunopre-
cipitation (IP) of V5-C, V5-AC, and V5-eGFP (as a control for
background binding) using an anti-V5 tag antibody (Supplemen-
tary Fig. 1b). Three independent pulldown samples from each cell
line were subjected to nano-liquid chromatography and tandem
mass spectrometry (nLC-MS/MS) under label-free (LFQ) condi-
tions. Potential interactors were selected based on (1) consistent
identification with at least two peptide spectral matches in all V5-
C or V5-AC biological replicate samples and absent in the V5-
eGFP controls, (2) intensity-based absolute quantification (iBAQ)
intensity normalization50 ranking, and (3) SAINTq51 analysis
(Supplementary Fig. 1c).
To construct PPI networks, UniProt IDs were converted to Ae.
aegypti gene stable IDs in VectorBase52 (AaegL5.3 release) and
interaction networks generated in StringDB53 with a cut-off
combined score of at least 0.7. Networks were visualized in
Cytoscape54 and gene ontology (GO) and pathway enrichment
analyses performed in VectorBase and DAVID55. Orthologs of
interactors in Drosophila melanogaster or Homo sapiens were
confirmed through OrthoDB56 or by conducting homology
searches using BLASTP algorithm. These were mapped using
FlyBase57 (FB2020_05 release) and HGNC58, respectively.
Inferred annotations were used to characterize the generated
networks with data mining for potential PPI in BioGRID59.
The selection criteria of the interactome data resulted in the
stringent identification of 148 and 47 potential mosquito protein
interactors with ZIKV C and AC, respectively (Venn diagram,
Fig. 1b; Supplementary Tables 1 and 2), and 38 with both C and
AC. A number of ribosomal proteins were identified, while other
enriched pathways clustered within the network contained several
structural and nucleotide-binding proteins and transporters
(Fig. 1c). The relative abundance of proteins in the interactomes
allowed us to estimate their relative frequency of binding to the
bait proteins. For both C and AC interactors, AAEL015065 (Ae.
aegypti SPTAN1) was the most abundant interacting protein
based on the number of peptide spectral matches. AAEL003530
(Ae. aegypti RPLP1) had the highest relative abundance using the
more sophisticated iBAQ and LFQ quantitation algorithms,
which normalize peptide spectral intensity by the predicted
peptide yield of each protein. GO analysis (Fig. 2a) showed that
most of the interactors were involved in transla-
tion (GO:0006412), metabolic processes (GO:0003461 and
GO:0009058), or as structural components of ribosomal com-
plexes (GO:0005840 and GO:0003735). Notably, ZIKV capsid
also interacted with pathways involved in carbon fixation,
tryptophan and fatty acid metabolism, and with a number of
proteasome subunits.
Interestingly, capsid was shown to interact with proteins of the
RNA interference (RNAi) pathway including Dicer-2 (Dcr2;
AAEL006794). The RNAi pathway, in particular the exogenous
siRNA pathway in which Dcr2 plays a key effector role, is an
antiviral response found in mosquitoes and other insects60–63.
Previously, it was shown that yellow fever virus (YFV) C protein
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Fig. 1 Developing Ae. aegypti Stable Mosquito Cell Lines for Studying ZIKV C and AC PPI. a Schematic showing plasmid constructs used to express V5-
tagged ZIKV C or AC under the control of a PUb promoter with ZeoR gene, and duplicated 2A autocleavage sequence. b Study pipeline using developed Ae.
aegypti-derived AF5 cell line stably expressing ZIKV C or AC to investigate vector-virus PPIs. Venn diagram showing the distribution of potential interactors
among immunoprecipitated proteins. c ZIKV capsid-Ae. aegypti PPI network of 157 interactors from IP proteomics. C and AC nodes (diamonds) with IP
proteomics interaction (gray edges) to host interactors (circles) and StringDB PPI (cyan edges). Gray highlights enclose nodes with broadly related
functions. List of protein interactors provided in Supplementary Tables 1 and 2.
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is a suppressor of RNAi, and the same effect has been proposed
for ZIKV capsid64. However in a separate study, ZIKV AC
expression was found to benefit an unrelated alphavirus, Semliki
Forest virus (SFV) in a Dcr2-independent manner65. To assess
this, RNAi sensor assays66 were performed in the stable cell lines
by co-transfecting firefly luciferase (FFLuc) expression plasmid
(pIZ-Fluc) with dsRNA or siRNA targeting FFLuc. In this assay,
expression of ZIKV C or AC in the stable cell lines did not affect
mosquito RNAi activity, regardless of whether dsRNA or siRNA
was used to trigger silencing activity. This suggests that ZIKV C
and AC do not suppress the RNAi pathway in these cells, at least
(Supplementary Fig. 1d).
Fig. 2 ZIKV capsid interactors and dsRNA knockdown screen. a GO and KEGG pathway enrichment analyses of annotated interactors performed in
VectorBase and DAVID. Heat map shows significant enrichments (p-value < 0.05 in −log10) with Benjamini correction against the background gene set
with actual p-values provided in the Source Data file. Bars indicate gene count. b dsRNA knockdown screen of 24 interactors (Supplementary Table 3) in
AF5 cells with ZIKV-NLuc (MOI= 1) infection 24 hpt for 72 h. NLuc levels presented as mean ± SEM light units relative to dseGFP controls set to 1 from n
= 3 independent repeats. *p-value < 0.05 determined by two-tailed Student’s t-test, where vs. DMSO controls: AAEL006315 p= 0.041; AAEL002906 p=
0.002; AAEL012122 p= 0.008; AAEL009883 p= 0.001; AAEL020382 p= 0.042; AAEL012690 p= 0.023; AAEL008658 p= 0.009; AAEL010585 p=
0.037; other p-values provided in the Source Data file.
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Comparing the human orthologs of our mosquito interactors
with previous PPI studies35–37, interactors with ZIKV capsid in
human cells showed minimal overlap between proteomics data
sets and only one protein, GNL2, was common to all data sets
(Supplementary Fig. 1e, left panel). In addition, when comparing
our interactors to previous CRISPR genome-wide screens in
human cells67–69 during ZIKV infection, no common host factors
were identified (Supplementary Fig. 1e, right panel). The very
little overlap between our interactors with previous studies
highlights the cell-type and technique-specific effects of perform-
ing such studies to investigate host/vector-virus interactions.
To test some of these interactions, a dsRNA knockdown screen
was performed on 24 of the 38 shared potential interactors of C
and AC (Fig. 2b, Supplementary Table 3). AF5 cells were
transfected with gene-specific dsRNAs and infected 24 h post-
transfection (hpt) with ZIKV-NLuc48, a reporter virus expressing
Nanoluciferase. Results analyzed 72 h post-infection (hpi) showed
out of the 24 potential interactors tested, eight were identified to
have pro-viral activity during ZIKV infection (Fig. 2b, inserted
table). Interestingly, all pro-viral proteasome subunits:
AAEL06315 (Rpn1), AAEL002906 (Rpn2), and AAEL012122
(Rpn3), cluster together with TER94 (AAEL010585) in a
subnetwork involving the proteasome (Fig. 1c).
ZIKV C interacts with TER94-UPP and is important during
virus replication in mosquito cells. As part of the UPP that is
responsible for the majority of protein degradation in cells70,71,
TER94/VCP acts as a chaperone45,72,73 for ubiquitinated proteins
but can also perform other functions through co-factors that
facilitate binding with target proteins47,74. To determine the effect
of silencing TER94 or the proteasome subunit Rpn1 (as a
representative) on V5-C stability, knockdown experiments with a
cycloheximide chase assay were performed in AF5-V5-C cells
(Fig. 3a). The abundance of V5-C was more stable over time
when TER94 and Rpn1 were silenced, compared to the dseGFP-
transfected control (Fig. 3b). This indicates that ZIKV capsid may
undergo proteasomal degradation through ubiquitination, similar
to what has been shown for dengue virus (DENV) C protein75.
The interaction of ZIKV C and TER94 was confirmed by co-
immunoprecipitation (co-IP) assays using AF5-V5-C stable cell
lines transfected with a PUb expression plasmid66 encoding a
myc-tagged TER94. Since TER94 is involved in the UPP leading
to target protein degradation, the co-IP was carried out in the
presence of the proteasome and deubiquitinase (DUB) inhibitors,
MG132 and ML364, respectively. IP of myc-TER94 with anti-myc
antibody resulted in the pulldown of V5-C, while reciprocal
assays revealed pulldown of myc-TER94 by anti-V5 antibody
(Fig. 3c), thus confirming the interaction.
The pro-viral role of TER94 and Rpn1 was investigated further
by performing dsRNA knockdowns (silencing did not affect cell
viability; Supplementary Fig. 1f), followed by infection at 24 hpt
with ZIKV PE24376, a patient-derived ZIKV isolate. TER94 and
Rpn1 silencing significantly reduced ZIKV RNA levels as well as
virus titers when compared to the dseGFP controls (Fig. 3d). The
reduced levels of ZIKV under knockdown conditions may have
affected the viral replication cycle either early during genome
replication or later in virion assembly, which has been shown to
be UPP-dependent in DENV77.
To investigate whether TER94 and Rpn1 are required during
ZIKV replication, a ZIKV derived replicon system was used
(Fig. 3e, top panel). This allows the investigation of genome
replication without active infection and bypasses virus entry and
assembly steps without producing infectious virus particles,
unlike ZIKV-NLuc virus. AF5 cells under TER94 and Rpn1
knockdown conditions were co-transfected with in vitro
transcribed ZIKV NLuc-expressing replicon RNA, abbreviated
from here on to ZIKV Replicon for simplicity (Fig. 3e, bottom
panel). Luciferase levels measured 24 hpt showed that TER94 and
Rpn1 knockdown did not significantly affect ZIKV Replicon
activity relative to the dseGFP control (Fig. 3f). This suggests that
genome replication is not directly affected by the knockdown of
TER94 or Rpn1.
Since TER94 and Rpn1 act primarily on ubiquitinated proteins,
this led us to hypothesize that ZIKV C may also be ubiquitinated,
in a similar way to DENV nucleocapsid at the start of infection75.
To test this, an assay to detect ZIKV genome at early stages of
infection was designed (Fig. 3g). AF5 cells were transfected with
dsTER94 or dsRpn1 to knockdown host genes; dseGFP was used
as a non-targeting control. At 24 hpt, ZIKV PE243 was applied to
the cells and allowed to bind for 30 min on ice. The cells were
returned to 37 °C for simultaneous entry of virus particles. The
inoculum was aspirated to remove any unadhered virus particles
and replaced with fresh medium containing cycloheximide to stall
ribosomes on viral RNA. This prevented the synthesis of viral
proteins and thereby the generation of new viral RNAs.
At 1 and 2 hpi, internalized viral genomes were quantified by
RT-qPCR. Results showed that dsTER94 transfected cells had
significantly higher detectable ZIKV RNA compared to the
dseGFP control at 1 hpi but this was not the case at 2 hpi
(Fig. 3h). On the other hand, Rpn1 silenced cells showed no
difference in detectable ZIKV RNA at either timepoints compared
to controls. This suggests that proteasomal degradation at early
timepoints during infection may not be necessary to release the
viral genome and may be a by-product of C interaction with
TER94. The importance of capsid ubiquitination at early stages of
infection has been previously shown for DENV75. However, it is
likely that the knockdown of TER94 inhibited the release of
ubiquitinated capsid bound to the RNA genome, preventing
uncoating. This protected and preserved the genome, limiting
degradation and resulting in more detectable viral RNA at 1 hpi.
It has been shown that as flavivirus RNA genome is released into
the cytoplasm, it is degraded rapidly75,78 as exposed viral RNA
becomes accessible to nucleases79.
Ortholog mapping of mosquito interactors reveals human
TER94 is vital during ZIKV infection. TER94 is a highly con-
served protein across invertebrate and vertebrate species. It is
widely studied owing to its physiological importance of main-
taining protein homeostasis in cells80,81. In D. melanogaster,
dysregulation of this protein has been linked to retinal degen-
eration in adult flies and developmental issues of larvae82,83, while
in humans mutations have been implicated in several proteino-
pathies and malignancies44,45,84. VCP has also been shown to be
important in viral infections of avian coronavirus85, human
cytomegalovirus86, Sindbis virus (SINV)87, chikungunya virus88,
West Nile virus89, hepatitis C virus90, and more recently YFV91.
Its prominent role in the UPP and viral infections merits addi-
tional investigation during ZIKV infection in human cells.
Ortholog mapping across VectorBase, FlyBase, and HGNC was
performed for all mosquito protein interactors of ZIKV C and AC
associated with TER94 and proteasome subunits. These proteins
and their PPIs were highly conserved across D. melanogaster and
H. sapiens (Fig. 4a). To test the role of VCP during ZIKV
infection in human cells, two siRNAs targeting VCP (siVCP-1,
siVCP-2, or the combination of both) were transfected into A549
cells followed by infection with ZIKV-NLuc or ZIKV PE243. VCP
knockdown significantly reduced both reporter virus readings
and viral RNA compared to controls (Fig. 4b). Knockdown
efficiency of siRNAs was confirmed by immunoblots with no
effect on cell viabilities (Supplementary Fig. 2a, b).
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Verified and readily available chemical inhibitors for human
UPP proteins were used to inhibit specific proteins or steps in the
pathway (Fig. 4c) to determine those important during ZIKV
replication. Pyr-41 was used to inhibit ubiquitin recruitment by
E1 ligase preventing ubiquitination; VCP function was blocked by
DBeQ and EerI; DUB activity was suppressed by ML364; and
proteasomal degradation was avoided by treating with
MG13275,92–94. Cell viability assays were performed prior to this
experiment and only concentrations deemed to be non-cytotoxic
for each inhibitor were used (Supplementary Fig. 2c). A549 cells
were pretreated with Pyr-41 (75 μM), DBeQ (1 μM), EerI (1 μM),
ML364 (2 μM) and MG132 (20 μM) for 2 h prior to ZIKV PE243
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infection and the virus was allowed to replicate for 24 h in the
presence of inhibitors. It was observed that inhibition of
ubiquitination, VCP function, and proteasome activity signifi-
cantly reduced ZIKV RNA levels versus DMSO controls (Fig. 4d).
Inhibition of deubiquitination by ML364 did not affect ZIKV
replication.
To assess whether VCP-UPP proteins are needed at certain
timepoints during ZIKV infection in A549 cells, a drug time-of-
addition assay was designed (Fig. 4e) with ZIKV-NLuc infection.
Three conditions were tested: (1) pre-infection wherein cells were
treated with inhibitors 2 h prior to infection until 2 hpi; (2) co-
treatment wherein ZIKV-NLuc was incubated with inhibitors at
37 °C for 1 h, and the drug-inoculum added to cells for 2 h, and
(3) post-infection wherein cells were infected for 2 h before the
addition of inhibitors until 6 hpi. Following each treatment, the
culture media was replaced with fresh media and incubated for
24 h. Overall, the experiment showed that NLuc signal was
reduced only when cells were pre-treated with Pyr-41, DBeQ, and
EerI 2 h prior to infection versus DMSO-treated controls (Fig. 4f).
Treatment with most drugs post-infection also did not affect
NLuc levels. Treating cells with MG132 pre- or post-infection, but
not in the case of co-treatment, reduced ZIKV levels, which
implies that MG132 also affected virus replication steps post-
entry. Comparable to what has been observed before (Fig. 4d),
treatment with ML364 did not affect ZIKV replication. We
assume that VCP-UPP acts on ZIKV early during the infection of
A549 cells, similar to what has been observed with TER94 in AF5
cells. To validate this further, corresponding drug treatments at 2
hpi with ZIKV PE243 were performed, and viral RNA levels
measured. Similar results were observed (Supplementary Fig. 2d).
We also performed a time course infection assay to detect the
hampered start of infection in earlier timepoints. Indeed, results
showed that inhibiting VCP using DBeQ or EerI resulted in a
lower NLuc signal compared to DMSO control (with cyclohex-
imide as positive control) at 4 hpi and this difference persisted
until 24 hpi (Supplementary Fig. 2e). These data further support
the finding that ZIKV capsid interacts with TER94/VCP, and its
segregase function is critical in establishing ZIKV replication
early in the virus life cycle. In summary, data from both mosquito
and human cell experiments showed that the knockdown of
TER94/VCP and drug-mediated inhibition of VCP during ZIKV
infection resulted in reduced replication. This suggests a
conserved role for TER94/VCP during ZIKV infection in both
mosquito and human cells.
UBR5, a TER94/VCP co-factor needed during ZIKV infection.
It has been discussed that TER94/VCP function relies on co-
factors to provide specificity during binding and direct the fate of
target proteins; hence it was essential to identify potential co-
factors that interact with TER94/VCP during ZIKV infection. To
do this, data mining of VCP co-factors was performed in Bio-
GRID. As of writing, the database catalogued 953 human proteins
that potentially interact with VCP. These were cross-referenced to
151 human orthologs of our Ae. aegypti interactome data,
resulting in 33 proteins in common (Fig. 5a). GO analysis showed
that most proteins function as ribosomal components for protein
and RNA binding. Therefore, the interactors were mapped across
orthologs to identify potential TER94/VCP co-factors involved
during ubiquitination (Fig. 5b). A PPI network of the cross-
referenced orthologs involved in ubiquitination was constructed
showing 5 human proteins that were highly conserved across
species (Fig. 5c). Interestingly, only two proteins function as
ubiquitin-binding partners (GO:0043130) across insect species,
sequestosome 1 (SQSTM1/p62) and UBR5. SQSTM1 and UBR5
have D. melanogaster orthologs, Ref(2)P and Hyd, respectively.
Ae. aegypti counterparts of these proteins in our proteomics data
are AAEL026751 and AAEL020992, respectively.
Little is known about Ref(2)P in mosquitoes regarding its
physiological or antiviral function but in D. melanogaster it has
been shown to limit ZIKV infection95. Its human ortholog,
SQSTM1, has been linked to cellular regulatory pathways by
acting as an adaptor to VCP during autophagy and proteasomal
degradation45,96. SQSTM1 has been shown to affect flavivirus
replication where deficient levels limited RNA replication of
Japanese encephalitis virus (JEV), while overexpression sup-
pressed DENV replication97,98 in mammalian cells. Ae. aegypti
SQSTM1 (AAEL026751) knockdown did not affect ZIKV
replication as shown in our dsRNA knockdown screen (Fig. 2b).
To determine if this finding was specific for mosquito cells,
siRNAs against SQSTM1 (siSQSTM1-A, siSQSTM1-B, or com-
bined) were tested in A549 cells (Supplementary Fig. 2a, b).
Similarly, to what was observed in AF5 cells, SQSTM1 silencing
Fig. 3 ZIKV C interacts with TER94 and Rpn1 during ZIKV infection in mosquito cells. a Schematic of cycloheximide chase assay of AF5-V5-C cell line
under knockdown conditions with cell lysates obtained at 0, 4, and 8 h post-cycloheximide treatment. b Densitometry of n= 3 independent cycloheximide
chase assay immunoblots of AF5-V5-C cells under TER94 and Rpn1 knockdown conditions. Improved V5-C stability versus dseGFP controls was observed
with band intensities (γ-tubulin loading control) presented as mean ± SEM relative signal to 0 h timepoint. **p-value < 0.01 determined by two-tailed two-
way ANOVA with Tukey’s multiple comparisons test where dsTER94 vs. dseGFP at 4 h p < 0.001, 8 h p < 0.001; dsRpn1 vs. dseGFP at 4 h p < 0.001, 8 h p <
0.001; dseGFP 0 vs. 4 h p < 0.001, vs. 8 h p < 0.001. Exact p-values cannot be computed. Representative blots with anti-V5 and anti-γ tubulin antibodies is
presented. c Representative immunoblots from n= 3 independent co-IP assays showing ZIKV C-TER94 interaction using AF5-V5-C cell line transfected
with pPUb-myc-TER94. Immunoprecipitation conducted using anti-V5 or anti-myc antibodies. d TER94 and Rpn1 knockdown in AF5 cells and infection for
72 h with ZIKV PE243 (MOI= 1) showed reduced virus replication. Viral RNA was measured 72 hpi by RT-qPCR shown as mean ± SD fold change (2
−ΔΔCT) relative to S7 gene and dseGFP controls set to 1. Released virus particles were measured by plaque assay with virus titers in PFU/mL (Log10 mean
± SEM). *p-value < 0.05, **p-value < 0.01 determined by two-tailed Student’s t-test of n= 3 independent repeats for ZIKV PE243 RT-qPCR dsTER94 p=
0.025, dsRpn1 p= 0.005; for ZIKV PE243 plaque assay dsTER94 p= 0.040, dsRpn1 p= 0.028. e Top panel, schematic of ZIKV NLuc-expressing replicon
construct, NLuc reporter followed by last 30 codons of envelope (E30). Bottom panel, replicon assay design in AF5 cells at 24 hpt of dsTER94 and dsRpn1
with ZIKV Replicon RNA co-transfected with pIZ-Fluc plasmid (transfection control). f ZIKV Replicon activity following TER94 and Rpn1 knockdown in AF5
cells was measured by dual-luciferase assay (NLuc/FFLuc ratio) expressed as mean ± SEM light units relative to dseGFP controls set to 1 from n= 3
independent repeats. *ns= not significant based on two-tailed Student’s t-test where dsTER94 p= 0.638, dsRpn1 p= 0.930. g Schematic of ZIKV genome
detection assay to measure viral RNA levels internalized into the cell during early stages of infection. At 24 hpt of dsRNA, cells were infected with ZIKV
PE243 (MOI= 10) on ice for 30min to allow simultaneous entry of virus particles. The inoculum was replaced with fresh media with cycloheximide and
incubated at 28 °C before total RNA was isolated at 1 and 2 hpi. h ZIKV RNA levels shown as mean fold change (2-ΔΔCT ± SD) from CT values normalized
to S7 gene and dseGFP controls set to 1 from n= 3 independent repeats. *p-value < 0.05 determined by two-tailed Student’s t-test compared where
dsTER94 vs. dseGFP at 1 hpi p= 0.016, 2 hpi 0.276; dsRpn1 vs. dseGFP at 1 hpi p= 0.484, 2 hpi p= 0.952; and between timepoints (1 vs. 2 hpi) for
dsTER94 p= 0.045, dsRpn1 p= 0.756. Source Data file provided.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22966-8 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2766 | https://doi.org/10.1038/s41467-021-22966-8 | www.nature.com/naturecommunications 7
in A549 cells did not affect ZIKV replication (Fig. 5d, left panel),
unlike the previous reports involving JEV and DENV.
The other potential TER94/VCP co-factor, UBR5 is an E3
ubiquitin ligase that recognizes protein degradation signals or
degrons enabling K11/K48 ubiquitination of internal lysine
residues99–101. The role of UBR5 in oncogenesis has been
reviewed extensively highlighting its function in cellular devel-
opment and cell cycle regulation102. A recent study describes the
interaction of UBR5 with VCP, leading to Wnt signaling pathway
inactivation103. Initially, AeUBR5 was not included in the dsRNA
knockdown screen as although it was identified in three AC
samples, it only appeared in two C IP proteomics samples. To test
the role of UBR5 during ZIKV infection, siRNAs against UBR5
(siUBR5-A, siUBR5-B, or combined) were transfected into A549
cells (Supplementary Fig. 2a, b). Following infection with ZIKV-
NLuc, silencing of UBR5 resulted in significantly reduced NLuc
readings relative to siNeg controls (Fig. 5d, right panel).
Given the results in human cells, it was of interest to know if
Ae. aegypti UBR5 (AAEL020992; AeUBR5) affected ZIKV
replication. Infection experiments in AF5 cells transfected with
dsAeUBR5 were performed. Knockdown efficiency of dsAeUBR5
was checked by RT-qPCR and was not found to affect cell
viability (Supplementary Fig. 1f). Infecting with either ZIKV-
NLuc (MOI= 1) or ZIKV PE243 (MOI= 1) for 72 h showed
significantly reduced virus replication versus controls, with less
infectious virus released as shown by ZIKV PE243 plaque assay
done in parallel (Fig. 5e).
To provide evidence to the interaction of TER94 and AeUBR5
in relation to ZIKV C, co-IP assays in AF5-V5-C cells under
AeUBR5 knockdown conditions were carried out. Briefly, stable
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cells were transfected with myc-TER94 expressing plasmids for
48 h and transfected with dsAeUBR5 or dsLacZ controls. Assays
were performed with MG132 and ML364 as previously
mentioned to limit the effect of degradation. Immunoblots
showed that knockdown of AeUBR5 resulted in the loss of
interaction between ZIKV C and TER94 (Fig. 5f).
The effect of AeUBR5 silencing on ZIKV C protein degrada-
tion was also investigated. A cycloheximide chase assay was
performed as above under AeUBR5 knockdown conditions in the
AF5-V5-C cell line. Silencing AeUBR5 improved V5-C protein
stability compared to controls, with minimal degradation within
the 8 h of cycloheximide treatment (Fig. 5g). This result is
comparable to the effect of silencing TER94 on V5-C stability
(Fig. 3d). We conclude that less ZIKV C was targeted for
degradation when AeUBR5 was silenced. Furthermore, AeUBR5
knockdown also does not affect ZIKV Replicon signal, similar to
TER94 silencing (Fig. 5h). Overall, this suggests a pro-viral role
for UBR5 during ZIKV infection concurrent with previous results
observed with TER94. These data corroborate the hypothesis that
ZIKV capsid can be degraded by the proteasome through TER94/
VCP segregation with UBR5 as a co-factor.
Discussion
Here, we present a method for studying Ae. aegypti-virus PPIs
using stable mosquito cell lines expressing virus proteins. These
were generated in a mosquito cell line expression system we had
previously developed66. Using the AF5 cell line, a single cell-
derived clone from Aag2 cells, allows future work on the iden-
tified interactors to be done using CRISPR-Cas9 knockout or
knock-in experiments66. In addition, AF5 cells exhibit better
transgene expression without sacrificing growth kinetics and
arbovirus infectivity104, making it well suited for molecular
experiments and developing stable mosquito cell lines.
This system can be easily adapted to investigate further ZIKV
proteins, or those of other mosquito-borne arboviruses, as well as
endogenous mosquito proteins. With a pipeline of investigation
that utilizes proteomics data, network analyses, bioinformatics
tools, and in vitro experiments, we were able to identify and test
pro-viral mosquito proteins that have orthologs in humans. We
provide new data and implications relating to how ZIKV infec-
tion occurs in vector cells and extrapolate the key findings to
human cells. Although, a number of proteomics-based studies on
arbovirus-vector interactions have been conducted in cells and
whole organisms105–108, our cell line system opens up the
potential to study more pronounced PPIs as it captures a global
interactome not restricted by molecular changes caused by virus
replication cycles where transient interactions are often lost. We
acknowledge that some interactions may only take place in the
context of virus infections and would not be captured here.
However, this system provides a toolkit approach for the study of
individual, or combinations of viral proteins at the cellular level.
This makes it highly flexible, robust, and complementary to
recent approaches to PPI studies of ZIKV infection in vertebrate
cells36,37. It may also be used as an alternative to screening
approaches using Y2H libraries42 or D. melanogaster systems that
have been used, for example, to identify TER94/VCP interaction
with SINV87. Moreover, it provides a more vector-focused
approach to investigating PPI as shown by the very minimal
overlap between previous PPI and genome-wide screen studies.
By using gene silencing and pharmacological approaches to
dissect ZIKV-TER94/VCP interactions, we were able to show
how vital these interactions are in establishing infection in both
mosquito and human cells. This interaction also expands our
understanding of mosquito UPP where a novel ubiquitin that
targets DENV E for degradation was recently discovered109.
Notably, VCP has never been implicated in other interactome
studies involving ZIKV proteins in human cells35–37, but has been
recently identified to interact with ZIKV NS4B in forming virus
replication factories110. We propose a model where TER94/VCP,
along with UBR5 as a co-factor, is critical for ZIKV infection
post-fusion, where capsid bound to genomic RNA is ubiquiti-
nated following the UPP model (Fig. 6). UBR5 directs TER94/
VCP interaction with C, eventually orchestrating the disassembly
of nucleocapsid structures, thereby exposing the viral RNA gen-
ome to the cytoplasm. As a consequence, C can be degraded by
proteasomal complexes. This hypothesis corroborates structural
studies on ZIKV capsid and genome encapsulation27,28. Although
we do not yet fully understand the detailed mechanism of TER94/
VCP interaction with capsid and the role of UPP proteins,
including UBR5, our data provide further proof that ubiquitina-
tion of viral proteins is essential during infection. Diving deeper
into these interactions with biochemical approaches will be
necessary to investigate the underlying mechanisms involved.
VCP has been hypothesized to play a role in the ubiquitination
of DENV C and subsequent uncoating of DENV genome in
human cells75. It was also recently investigated during YFV
infection91. Although a different drug-screening-based approach
was used in mammalian cells, the results of our study support
their findings, critically linking Ae. aegypti TER94 to flavivirus
capsid and other UPP components. Although VCP interaction
Fig. 4 Ortholog mapping of TER94 and proteasome subunits reveal conserved host factors during ZIKV infection in human cells. a ZIKV capsid-Ae.
aegypti TER94 and proteasome subunits PPI (blue nodes) from our proteomics data (gray edges) with D. melanogaster (green nodes) and H. sapiens (gray
nodes) orthologs. Cyan edges are StringDB PPI. Orthologs connected by dashed lines. b VCP silencing in A549 cells with siRNAs (siVCP-1 or siVCP-2
compared to siNeg; siVCP-1 and siVCP-2 (siVCP-1+ 2) compared to double amounts of negative siRNAs (siNeg2X) and infected with ZIKV-NLuc (MOI=
10) or ZIKV PE243 (MOI= 10) 72 hpt for 24 h reduced ZIKV levels. Results from n= 3 independent repeats shown as mean ± SEM light units or mean ±
SD fold change (2−ΔΔCT) of CT values normalized to GAPDH and siNeg controls set to 1. *p-value < 0.05, **p-value < 0.01 determined by two-tailed
Student’s t-test for ZIKV-NLuc siVCP-1 p= 0.037, siVCP-2 p= 0.011, siVCP-1+ 2 p= 0.033; for ZIKV PE243 RT-qPCR siVCP-1 p= 0.002, siVCP-2 p=
0.015, siVCP-1+ 2 p= 0.009. c A general model of VCP-UPP in human cells showing different steps from ubiquitination of target proteins (T) on a
substrate (S). Segregase function of VCP with a co-factor (Co) leads to proteasomal (P) degradation. Chemical inhibitors of UPP used in this study and
their stage of action are indicated. d Treating A549 cells with chemical inhibitors 2 h pre-infection of ZIKV PE243 (MOI= 10) reduced viral RNA levels
versus DMSO controls when ubiquitination (Pyr-41), VCP (DBeQ and EerI), and proteasome (MG132) activities were suppressed. N= 3 independent
repeats shown as mean fold change (2-ΔΔCT ± SD) of CT values normalized to GAPDH and DMSO controls set to 1. ns= not significant, *p-value < 0.05,
**p-value < 0.01 determined by two-tailed Student’s t-test where Pyr-41 p= 0.021; DBeQ p= 0.044; EerI p= 0.007; ML364 p= 0.237; MG132 p= 0.009.
e Time-of-addition assay of chemical inhibitors during ZIKV-NLuc (MOI= 10) infection in A549 cells. Drug treatments done: 1) pre-infection [pre-]; 2) co-
treatment [co-], and 3) post-infection [post-]. f Treatment of A549 with Pyr-41, DBeQ, EerI, MG132 at 2 h pre-infection reduced virus levels versus DMSO
controls. N= 3 independent repeats presented as mean ± SEM light units relative to DMSO control set to 1. *p-value < 0.05, **p-value < 0.01 determined
by two-tailed Student’s t-test where pre- Pyr-41 p= 0.019, DBeQ p= 0.046, EerI p= 0.039, MG132 p= 0.012; for post- MG132 p= 0.003; other p-values
provided in the Source Data file.
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with viruses has been explored widely, most studies involved
mammalian systems85,86,88,89,111. Here, we show how its Ae.
aegypti ortholog, TER94, behaves similarly during ZIKV infection
in vector cells, improving our understanding of common and
diverging aspects of infection across host cells.
The UPP is a multistep process with proteasomal degradation
as the end result, and we have shown that the function of UBR5
and TER94 may be a rate-limiting step during the early stages of
ZIKV infection. Although a proteomics study involving ZIKV
infection of C6/36 cells suggested that proteasome activity was
deemed important for virus entry108, it has also been shown to be
important in DENV egress112 and virion production77. In addi-
tion, the UPP has been hypothesized to be important at early
stages of JEV94, porcine circovirus113, murine coronavirus114, and
influenza A virus115 infections. These reports show the diversity
of roles the UPP plays during virus infections and is further
supported by what we have observed in our results.
This is to our knowledge, the first time UBR5 has been linked
to TER94/VCP as a co-factor in its interaction with a virus.
Previous studies have described UBR5 function in regulatory
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pathways and cancer100,102,103 but not much is known about how
it functions in tandem with TER94/VCP during viral infections.
This merits further investigation. Altogether, this study adds
novel information on the early stages of ZIKV-vector/host cell
interactions, with key aspects conserved in arthropod and verte-
brate cells, and it will be of importance to the field to compare
this to other flaviviruses.
Methods
Cells. Ae. aegypti AF5 cells, clonally derived from Aag2 cells66,104 were previously
used for CRISPR-Cas9 knockouts experiments. The AF5 cells were grown in L-15
medium with GlutaMAX (Thermo Fisher Scientific) supplemented with 10%
tryptose phosphate broth (TPB; Thermo Fisher Scientific), 10% fetal bovine serum
(FBS; Thermo Fisher Scientific), and penicillin-streptomycin (100 units/mL and
100 μg/mL, respectively, Thermo Fisher Scientific) at 28 °C with no added CO2.
Stable cell lines (AF5-V5-C, AF5-V5-AC, and AF5-V5-eGFP) were also grown in
the same conditions as stated with the addition of Zeocin (1 g/mL; Invivogen).
A549 cells (human male Caucasian lung carcinoma cells; ECACC, Cat# 86012804)
were grown in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS at
37 °C with 5% CO2. A549 cells stably expressing bovine viral diarrhea virus
NPro116 cells (A549-Npro) were a kind gift from R.E. Randall (University of St
Andrews, UK) were grown in similar conditions as A549 cells but with the addition
of Blasticidin (100 mg/mL, Invivogen) to keep the transgene. Cell lines made for
the study are available upon request.
Viruses. ZIKV-NLuc reporter virus was rescued from a ZIKV icDNA clone, pCCI-
SP6-ZIKV-NLuc based on a Brazilian ZIKV isolate48. ZIKV PE243 (ZIKV/H.
sapiens/Brazil/PE243/2015; GenBank: KX197192.1; https://www.ncbi.nlm.nih.gov/
nuccore/KX197192.1) is a Brazilian clinical isolate from a patient, which we have
previously characterized76. All viruses were grown in A549-NPro cells in DMEM
with 2% FBS at 37 °C with 5% CO2 for five days. Culture supernatants were
collected and centrifuged at 443 × g for 5 min. Virus titers were determined by
plaque assay and aliquots stored at −80 °C.
Plasmids. Plasmids used in mosquito cells where the expressed genes are placed
were under the control of a polyubiquitin promoter (PUb) from pGL3-PUb49
Fig. 5 UBR5 is a TER94/VCP co-factor during ZIKV infection. a Overlap of BioGRID VCP interactors and human orthologs of Ae. aegypti ZIKV capsid
interactors. b GO analysis showing cross-referenced VCP interactors from BioGRID involved in ubiquitination across H. sapiens (Hsap), D. melanogaster
(Dmel), and Ae. aegypti (Aaeg). The heat map indicates significance values (in −Log10 p-value) of only significant enrichments (p-value < 0.05) with
Benjamini correction against the background gene set with actual p-values provided in the Source Data file. Bars indicate gene count. c Ortholog-PPI
network of VCP interactors involved in ubiquitination from BioGRID. H. sapiens, D. melanogaster, and Ae. aegypti proteins are gray, green, and blue nodes,
respectively. BioGRID interaction edges in magenta. StringDB PPI in cyan edges. Orthologs are connected by dashed lines. Mosquito interactors to ZIKV C
and AC are linked by gray edges. d siRNA silencing of UBR5 and SQSTM1 in A549 cells for 72 h prior to infection with ZIKV-NLuc (MOI= 10) for 24 h.
UBR5 knockdown resulted in reduced NLuc levels versus controls with NLuc readings shown as mean ± SEM light units relative to siNeg controls set to 1
from n = 3 independent experiments. ns = not significant, *p-value < 0.05 determined by two-tailed Student’s t-test where siSQSTM1-A p= 0.099;
siSQSTM1-B p= 0.642; siSQSTM1-A+ B p= 0.091; siUBR5-A p= 0.043; siUBR5-B p= 0.010; siUBR5-A+ B p= 0.041. e In AF5 cells, AeUBR5
knockdown using dsRNA and infection with ZIKV-NLuc (MOI= 1) or ZIKV PE243 (MOI= 1) at 24 hpt. ZIKV levels at 72 hpi showed reduced NLuc signal
and viral RNA versus dseGFP controls. ZIKV PE243 plaque assay also showed reduced titers in dsAeUBR5. N = 3 independent experiments presented as
mean ± SEM light units or fold change (2−ΔΔCT ± SD) with CT values normalized to S7 gene relative to dseGFP controls set to 1. Virus titers in PFU/mL
(Log10 mean ± SEM). *p-value < 0.05 determined by two-tailed Student’s t-test for ZIKV-NLuc p= 0.021; ZIKV PE243 RT-qPCR p= 0.040; ZIKV PE243
plaque assay p= 0.045. f Representative immunoblots from n= 3 independent co-IP assays performed in AF5-V5-C cells under AeUBR5 knockdown
conditions and transiently expressing myc-TER94 was performed. Knockdown of AeUBR5 resulted in the loss of V5-C pulldown by anti-myc antibody. g
Densitometry of n= 3 independent cycloheximide chase assay immunoblots in AF5-V5-C cells at 24 hpt of dsAeUBR5. Band intensities (γ-tubulin loading
control) shown as mean ± SEM signal relative to 0 h timepoint. *p-value < 0.05 determined by two-tailed two-way ANOVA with Tukey’s multiple
comparisons test where dsAeUBR5 vs. dseGFP at 4 h p= 0.263, 8 h p= 0.015; dsAeUBR5 at 0 vs. 4 h p= 0.002, vs. 8 h p < 0.001; for dseGFP at 0 vs. 4 h
p < 0.001, vs. 8 h p < 0.001. Exact p-values cannot be computed. h AF5 cells under AeUBR5 knockdown conditions were transfected with in vitro
transcribed ZIKV Replicon RNA together with pIZ-FLuc, and at 24 hpt the signal intensities were measured by dual-luciferase assay. NLuc/FFLuc ratio
expressed as mean ± SEM light units relative to dseGFP controls set to 1 from n = 3 independent experiments. ns = not significant determined by two-
tailed Student’s t-test where p= 0.379. Source Data file is provided.
Fig. 6 Proposed model of TER94/VCP-mediated ZIKV uncoating. Ubiquitination of ZIKV C by ligases (E1, E2, and E3) allows interaction with UBR5
leading to the involvement of VCP/TER94. Segregation allows disassembly of the nucleocapsid, uncoating the RNA genome into the cytoplasm for
translation. Degradation of ZIKV C by proteasomal complexes (P) can be a by-product of this interaction.
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(Addgene, Cat# 52891) originally expressing FFLuc. The luciferase coding sequence
was removed, leaving a PUb backbone plasmid (called pPUb), which was used to
generate a plasmid expressing V5-eGFP (pPUb-V5-eGFP66). pPUb-V5-eGFP
contains a ZeoR gene, two copies of 2 A autoprotease sequence of Thosea asigna
virus, and a V5-tag. This was used as the backbone to generate constructs
expressing V5-tagged ZIKV C/AC by replacing the eGFP coding sequence. The
eGFP coding sequence was removed by restriction enzyme digestion using XhoI
(New England BioLabs, Cat# R0575S) and BsrGI (New England BioLabs, Cat#
R0146S) with CIP (New England Biolabs, Cat# M0525S). Coding sequences for C
(315 bp) or AC (369 bp) were PCR amplified from pCCI-SP6-ZIKV using gene-
specific primers (ZCFor with ZIKVAC_R or ZIKVC_R primers, Supplementary
Table 4) with 15 bp homologous overlaps to the backbone using CloneAmp HiFi
PCR Premix (Takara Bio). The sequence is identical to C or AC in ZIKV isolate
PE24376. For the myc-tagged TER94 expression plasmid (pPUb-myc-TER94), a
pPUb-myc-eGFP plasmid previously made66 was used as the backbone. eGFP
coding sequence was removed using restriction with XhoI and FseI (New England
BioLabs, Cat# R0588S) in the presence of CIP. TER94 coding sequence was PCR
amplified from reverse-transcribed total RNA extracted from AF5 cells using gene-
specific primers (XhoI_TER94_F with TER94_FseI_R primers, Supplementary
Table 4) with homologous overlaps and CloneAmp HiFi PCR Premix. Each
amplicon of interest was gel purified and subjected to In-Fusion cloning (Takara
Bio) following the manufacturer’s protocol. The mix was then transformed in
Stellar Competent Cells (Takara Bio, Cat# 636763) and grown on LB agar with
ampicillin (100 μg/μL) for 24 h at 37 °C. Sequences of inserts in bacterial colonies
were confirmed using Sanger sequencing. DNA preparations used in the studies
were made using PureLink HiPure Plasmid Maxiprep kit (Thermo Fisher Scien-
tific) as per manufacturer’s guidelines. Sequences and primers analyzed in Gen-
eious Prime 2021.0.3.
Antibodies. Primary antibodies: mouse monoclonal anti-V5 tag antibody (Abcam,
Cat# ab27671) was used for IP, co-IP, immunoblotting, and immunofluorescence
assays; mouse monoclonal anti-myc tag antibody (Abcam, Cat# ab32) was used for
co-IP assays and immunoblotting; mouse monoclonal anti-UBR5 (Proteintech
Group, Cat# 66937-1-Ig) and anti-β catenin (Cell Signaling Technology, Cat# 2677
s) were used for immunoblotting; and rabbit polyclonal anti-VCP (Proteintech
Group, Cat# 10736-1-AP), anti-SQSTM1 (Proteintech Group, Cat# 18420-1-AP),
anti-V5 tag (Abcam, Cat# ab9116), anti-γ-tubulin (Abcam, Cat# ab11317), and
anti-β catenin (Abcam, Cat# ab16051) antibodies were used for immunoblotting.
Secondary antibodies for immunoblotting: goat polyclonal anti-mouse HRP-con-
jugated (Thermo Fisher Scientific, Cat# A16072), anti-mouse IgG (H+ L) DyLight
800 (Thermo Fisher Scientific, Cat# SA5-35521), and anti-rabbit IgG (H+ L)
DyLight 680 (Thermo Fisher Scientific, Cat# 35568). Secondary antibodies for
immunofluorescence microscopy: goat anti-mouse Alexa Fluor 568 (Thermo Fisher
Scientific, Cat# A-11031).
Development of stable mosquito cell lines. To generate the stable cell lines, 20 μg
of pPUb-V5-eGFP, pPUb-V5-C or pPUb-V5-AC were initially linearized using
NotI-HF (New England BioLabs, Cat# R3189S) restriction enzyme at 37 °C for 24 h
and purified using QIAquick PCR purification kit. AF5 cells seeded at 2.5 × 105
cells/well in T25 flasks were transfected with 5 μg of the linearized plasmid using
10 μL DharmaFECT 2 (Horizon Discovery) in Opti-MEM (Thermo Fisher Scien-
tific). After 24 hpt, the culture media was replaced with fresh L-15 supplemented
with Zeocin (1 g/mL at 1:1000, Invivogen) and thereafter replaced every 4 days for
30 days. An aliquot of cells was obtained 30 days post-transfection and lysed for
immunoblotting of V5 tag. The remaining cells were then split and maintained in
L-15 supplemented with Zeocin (1 g/mL at 1:500).
Cycloheximide chase assay. To evaluate ZIKV C degradation during knockdown
conditions of TER94, Rpn1, and AeUBR5, AF5-V5-C cells seeded at 2.5 × 105 cells/
well in 24-well plates were transfected correspondingly with 300 ng dsRNA or
dseGFP control with 2 μL DharmaFECT 2 (Horizon Discovery) in Opti-MEM.
Cycloheximide chase assay was performed 24 hpt by adding cycloheximide (1 μg/
μL, Sigma-Aldrich) for 0, 4, and 8 h.
IP and co-IP assays. For IP samples for proteomics, AF5 stable cell lines grown in
T150 flasks were scraped and spun at 443 × g for 5 min to pellet the cells. The
supernatant was removed, and the cell pellet washed with phosphate-buffered
saline (PBS; Thermo Fisher Scientific) and spun down. Cells were then resuspended
in IP lysis buffer (20 mM HEPES [pH 7.4]; Thermo Fisher Scientific], 150 mM
NaCl, 5 mM MgCl2, 1× Halt protease inhibitor cocktail [1:100 dilution; Thermo
Fisher Scientific], and 1% Triton X-100) and incubated on ice for 30 min. Lysed
cells were then centrifuged at 16,000 × g for 20 min at 4 °C. The supernatant was
incubated with mouse monoclonal anti-V5 tag antibody (1:200 dilution; Abcam,
Cat# ab9116) for 2 h at 4 °C on a rotator disk. Protein G Dynabeads (Thermo
Fisher Scientific) were equilibrated by washing with cold IP wash buffer (same as
the IP lysis buffer without protease inhibitors) for at least an hour at 4 °C on a
rotator disk. To the supernatant-antibody mix, 30 μL pre-equilibrated Protein G
Dynabeads was then added and incubated for another hour at 4 °C on a rotator
disk. The slurry was then placed on a magnetic rack and washed three times with
IP wash buffer for 5 min and transferred to a fresh tube. The beads were finally
resuspended in 50 μL IP wash buffer, 20 μL 4× Bolt LDS (Thermo Fisher Scientific),
and 10 μL 10× Bolt Reducing Agent (Thermo Fisher Scientific). An aliquot was
used for immunoblotting. Independent triplicate IP assays were done for pro-
teomics analysis. For co-IP, AF5-V5-C cells were seeded into T150 flasks and
allowed to adhere overnight. The cells were then transfected with 30 μg of pPUb-
myc-TER94 with 15 μL DharmaFECT 2 in Opti-MEM. After 72 h, transfected cells
were treated with 10 μMMG132 (Merck) and 10 μMML364 (Sigma-Aldrich) for 1
h prior to performing the IP assay mentioned earlier. IP lysis and wash buffers were
modified by adding 10 μM MG132 and 10 μM ML364. For the co-IP assay under
AeUBR5 knockdown conditions, stable cells transiently expressing myc-TER94
were transfected with 300 ng dsAeUBR5 or dsLacZ at 24 h prior to lysis. A reci-
procal pulldown assay of myc-TER94 was also performed using mouse anti-myc
tag antibody (1:200; Abcam, Cat# ab32) to co-immunoprecipitate V5-C. Input cell
lysate and IP samples were then probed for either V5-C or myc-TER94.
Immunoblotting. Samples lysed using 1× Bolt LDS Sample Buffer with 1× Bolt
Reducing Agent (Thermo Fisher Scientific) were heated at 95 °C for 10 min.
Samples were then separated on Bolt 4-12% Bis-Tris Plus gels (Thermo Fisher
Scientific) and transferred to 0.45 μm nitrocellulose membrane (Thermo Fisher
Scientific) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). Membranes
were then blocked with 5% (w/v) non-fat dry milk in PBS-Tween (PBS with 0.1%
Tween 20) for at least 1 h. Membranes were then incubated with primary anti-
bodies in 2% (w/v) non-fat dry milk in PBS-Tween for 1 h using mouse mono-
clonal anti-V5 tag antibody (1:2000, Abcam, Cat# ab27671), mouse monoclonal
anti-myc tag antibody (1:2000, Abcam, Cat# ab32), mouse monoclonal anti-UBR5
(1:2000, Proteintech Group, Cat# 66937-1-Ig), rabbit polyclonal anti-VCP (1:2000,
Proteintech Group, Cat# 10736-1-AP), anti-SQSTM1 (1:2000, Proteintech Group,
Cat# 18420-1-AP) or anti-V5 tag (1:2000, Abcam, Cat# ab9116). To detect
housekeeping proteins in the same gel, rabbit anti-γ-tubulin (1:2000, Abcam, Cat#
ab11317), rabbit anti-β catenin (1:2000, Abcam, Cat# ab16051), or mouse anti-β
catenin (1:2000, Cell Signaling Technology, Cat# 2677 s) were used, when appro-
priate. Membranes were then washed three times with PBS-Tween for 10 min. In
case of the IP samples, membranes were incubated with polyclonal goat anti-mouse
HRP-conjugated secondary antibody (1:5000; Thermo Fisher Scientific, Cat#
A16072) for 1 h and washed three times with PBS-Tween for 10 min. Membranes
were then incubated in Amersham ECL Western Blotting Detection Reagent
(Merck, Cat# GERPN2109) and chemiluminescent bands detected using Gel Doc
XR+ with Image Lab software (v.4.1; Bio-Rad). For cycloheximide chase assay and
co-IP samples, membranes were incubated with goat anti-mouse DyLight 800
(1:5000; Thermo Fisher Scientific, Cat# SA5-35521) and/or goat anti-rabbit
DyLight 680 (1:5000; Thermo Fisher Scientific, Cat# 35568) secondary antibody
conjugated with a near fluorescent dye in 2% (w/v) non-fat dry milk in Tween-PBS
for 1 h. Membranes were again washed with Tween-PBS three times and viewed
using an Odyssey CLx with Image Studio (v.1.0.11; LI-COR Biosciences). Densi-
tometry analyses of immunoblot images performed in Image Studio Lite (v.5.2.5;
LI-COR Biosciences).
Immunofluorescence analysis. Immunostaining of AF5-V5-C or AF5-V5-AC
cells was performed by seeding 1.5 × 105 cells/well into poly-D-lysine treated 13
mm coverslips in 24-well plates. After 24 h cells were fixed with 4% formaldehyde
for 20 min, washed with PBS for 5 min, and permeabilized using 0.5% Triton X-100
in PBS for 10 min. After another PBS wash, coverslips were blocked with 5% FBS in
PBS for 1 h. Detection of V5-C or V5-AC was done for 1 h using monoclonal
mouse anti-V5 tag (1:500) antibody in 5% FBS in PBS. Coverslips were then
washed three times for 5 min with PBS and incubated with goat anti-mouse Alexa
Fluor 568 (1:1000; Thermo Fisher Scientific, Cat# A-11031) in 5% FBS in PBS for 1
h in the dark. Following three washes of PBS for 5 min, coverslips were washed
with ddH2O and mounted on glass slides with VECTASHIELD HardSet mounting
medium with DAPI (Vector Laboratories, Cat# H-1500). Glass slides were viewed
under a Zeiss LSM 710 confocal microscope with ZEN black 2011 version. Pho-
tomicrographs were analyzed in ZEN lite (v.3.3; Zeiss).
LFQ proteomics of IP samples. All proteomics experiments were performed at the
Fingerprints Proteomics Facility (University of Dundee, https://www.lifesci.dundee.
ac.uk/technologies/fingerprints-proteomics-facility). Proteins from IP samples were
initially separated by SDS-PAGE with gel selection processing, in-gel reduction/
alkylation, and in-gel trypsin digestion. Digested samples were then subjected to
nLC-MS/MS using an LTQ Orbitrap Velos Pro (Thermo Fisher Scientific). Raw MS
data were analyzed in MaxQuant (v1.6.3.4) with a 1% false discovery rate at the
protein and peptide spectrum match levels. Treating each raw file as a separate
fraction in the experimental design, the following parameters were observed: fixed
modifications were carbamidomethyl (C), variable modifications were oxidation
(M) and acetyl (protein N-terminal), LFQ and iBAQ were enabled, digestion was
with trypsin/P, and default options were used for all other search settings. Peptide
spectra were matched to a database containing: (i) the bait protein sequences; (ii)
the Ae. aegypti reference proteome (UP000008820 downloaded from UniProt117
using a version last updated 29 June 2020), edited to remove all of the multiple
instances of the ubiquitin sequence to prevent ambiguous assignments of
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ubiquitin-derived peptide spectra; (iii) a single instance of the ubiquitin sequence;
and (iv) the default MaxQuant list of common contaminants. Protein groups
matching to these databases were subsequently excluded if they were only identi-
fied by site, or if they were found on the common contaminants list (with the
exception of eGFP, which was also a bait protein). To select potential interactors,
the protein hits were scored based on replicate reproducibility between samples,
iBAQ normalization50, and SAINTq51. For further technical details on sample
processing and analysis see Data Availability.
cDNA synthesis, dsRNA synthesis, and RT-qPCR. Total RNA was extracted
from cells (pooled from 4 wells) using TRIzol (Thermo Fisher Scientific) following
the manufacturer’s instructions with the addition of glycogen during RNA pre-
cipitation to improve the yield. A 1 μg aliquot of RNA was used for cDNA synthesis
using Superscript III Reverse Transcriptase (Thermo Fisher Scientific) and random
primers (Promega, Cat# C1181). Gene-specific primers flanked with T7 RNA
polymerase promoters (Supplementary Table 5) and GoTaq G2 Flexi polymerase
(Promega) were used to obtain templates for dsRNA synthesis. Amplicons were gel
purified using QIAquick Gel extraction kit (Qiagen) with 1 μg used for in vitro
transcription with MEGAscript RNAi kit (Thermo Fisher Scientific) following the
manufacturer’s protocol. For quantitative PCR of ZIKV and genes of interest for
knockdown efficiency were performed using gene-specific qPCR primers (Sup-
plementary Table 6) and Fast SYBR Green Master Mix (Thermo Fisher Scientific)
in an ABI7500 Fast Real-Time PCR system with 7500 software (v.2.3; Thermo
Fisher Scientific) with S7 (for Ae. aegypti cells) and GAPDH (for A549 cells) as
housekeeping genes.
dsRNA knockdown and infection in Ae. aegypti cells. For the dsRNA knock-
down screen, candidate proteins were chosen based on function, availability of
supporting information, known interactions with other viruses, and excluding
ribosomal subunits and cytoskeleton proteins (Supplementary Table 3; Ae. agypti
mRNA sequences from https://www.ncbi.nlm.nih.gov/assembly/
GCF_002204515.2). To perform the dsRNA knockdown screen and TER94, Rpn1,
and AeUBR5 silencing, AF5 cells seeded at 2.5 × 105 cells/well in 24-well plates
were transfected with 300 ng of dsRNA or dseGFP as control with 2 μL Dharma-
FECT 2 (Horizon Discovery) in Opti-MEM. Cells were then infected 24 hpt either
with ZIKV-NLuc (MOI= 1) or ZIKV PE243 (MOI= 1) for 72 h. Cells infected
with ZIKV-NLuc were lysed with 1× PLB and NLuc readings measured using
Nano-Glo Luciferase Assay system (Promega, Cat# N1130) on GloMax Lumin-
ometer with Instinct software (v.2.0.1; Promega). For cells infected with ZIKV
PE243, total RNA was extracted using TRIzol following the manufacturer’s pro-
tocol and subjected to RT-qPCR. Parallel knockdown efficiencies of the dsRNAs
were also measured by RT-qPCR of gene transcripts and corresponding cell
viabilities were checked prior to the actual experimentation using CellTiter-Glo
assay (Promega, Cat# G7571).
ZIKV replicon assay. A ZIKV derived, NLuc expressing replicon, abbreviated
ZIKV Replicon, was designed based on a ZIKV subgenomic replicon48. The
replicon, under the control of an SP6 promoter, contained a coding sequence for
ZIKV capsid with its anchor domain, prME was replaced with an NLuc reporter,
while retaining the last 30 codons of E, followed by non-structural proteins. Using
MEGAscript SP6 Transcription kit (Thermo Fisher Scientific), the replicon was
in vitro transcribed. To knockdown interactors, AF5 cells seeded at 2.5 × 105 cells/
well in 24-well plates were transfected with 300 ng of dsRNA or dseGFP as control
using 2 μL DharmaFECT 2 in Opti-MEM. After 24 h, cells were co-transfected with
1 μg in vitro transcribed ZIKV Replicon RNA and 50 ng FFLuc expression plasmid
(pIZ-Fluc; transfection control) using 2 μL DharmaFECT 2 in Opti-MEM. Cells
were lysed 24 hpt using 1× PLB and NLuc and FFLuc levels were measured using a
Nano-Glo Dual-Luciferase Reporter Assay System (Promega, Cat# N1610) fol-
lowing the manufacturer’s protocol.
ZIKV genome detection assay. For the ZIKV genome detection assay at early
stages if infection, AF5 cells seeded at 2.5 × 105 cells/well in 24-well plates were
transfected with 300 ng of dsTER94, dsRpn1 or dseGFP control with 2 μL Dhar-
maFECT 2 in Opti-MEM. After 24 hpt, cells were infected with ZIKV PE243 (MOI
= 10) on ice with cycloheximide (1 μg/μL) for 30 min to allow simultaneous entry.
Any unadhered virus was removed by replacing with fresh L-15 medium with
cycloheximide. Cells were then incubated at 28 °C for 1 and 2 h. Total RNA was
extracted from each timepoint using TRIzol (Thermo Fisher Scientific) following
the manufacturer’s instructions and synthesized cDNA used for RT-qPCR of ZIKV
PE243 and dsRNA knockdown efficiency.
siRNA knockdown and infection in A549 cells. A549 cells were seeded at 1.5 ×
105 cells/well in 24-well plates and transfected with 5 pmol of each or both siRNA
against VCP (Thermo Fisher Scientific, Cat# s14767 and s14765), UBR5 (Thermo
Fisher Scientific, Cat# s28025 and s224201), SQSTM1 (Thermo Fisher Scientific,
Cat# s16960 and s16962), or 5 pmol (siNeg) or 10 pmol (siNeg2X) Silencer Select
Negative Control #2 (Thermo Fisher Scientific, Cat# 4390846) as a control with 2
μL DharmaFECT 2 (Horizon Discovery) for 72 h. Cells were infected with ZIKV-
NLuc (MOI= 10) or ZIKV PE243 (MOI= 10) for 24 h. Cells were lysed with 1×
PLB for ZIKV-NLuc infected cells or TRIzol for ZIKV PE243 infected cells. Cor-
responding knockdown efficiencies of each siRNA were checked by immunoblot-
ting using antibodies against VCP, SQSTM1, and UBR5. Cell viabilities 72 hpt were
also checked using CellTiter-Glo assay (Promega, Cat# G7571) as per manu-
facturer’s guidelines.
Chemical inhibitors and infection. A549 cells seeded at 1.5 × 105 cells/well in 24-
well plates were treated with chemical inhibitors against different proteins in the
UPP. Cell viability assays were performed to test the cytotoxicity of the drugs at
different concentrations at 24 h post-treatment with CellTiter-Glo assay (Promega,
Cat# G7571). A549 cells were treated with Pyr-41 (75 μM), DBeQ (1 μM), EerI (1
μM), ML364 (2 μM), MG132 (20 μM), and DMSO as control (0.1% in DMEM) for
2 h prior to ZIKV PE243 (MOI= 10) infection. Cells were incubated with the drug
(or DMSO control) and virus at 37 °C with 5% CO2 for 24 h. Total RNA was then
extracted from the cells using TRIzol following the manufacturer’s protocol and
viral RNA measured by RT-qPCR.
Drug time-of-addition assay. For the time-of-addition assay of UPP chemical
inhibitors, A549 cells at 1.5 × 105 cells/well were seeded in 24-well plates and
subjected into three different treatments: (1) pre-treatment (pre), (2) co-treatment
(co), and (3) post-treatment (post). The same drug concentrations were used as
mentioned above. All ZIKV-NLuc (MOI= 10) infections were done in the pre-
sence of the inhibitors or DMSO control. In case of pre-treatment, cells were
treated with chemical inhibitors or DMSO control for 2 h before infection until 2
hpi. Co-treatment involved incubating the virus with the drug for 1 h at 37 °C
before adding the drug with virus on to the cells for 2 h. For the post-treatment,
cells were first infected with virus for 2 h and the drugs added until 6 hpi. After
each treatment, the drug and inoculum were replaced with fresh media and the
cells incubated at 37 °C with 5% CO2 for 24 h. Cells were then lysed with 1× PLB
and NLuc readings measured using a GloMax Luminometer following the Nano-
Glo Luciferase assay (Promega, Cat# N1130) protocol.
ZIKV-NLuc infection time course. A549 cells were seeded at 1.5 × 104 cells/well in
96-well plates and treated with DBeQ (5 μM), EerI (5 μM), or cycloheximide (1 μg/
μL) for 2 h prior to infection with ZIKV-NLuc (MOI= 10). Infection was per-
formed in the presence of the drugs for 4 to 24 h. Cells were then lysed at 4 h
intervals using 1× PLB and NLuc readings measured using Nano-Glo Luciferase
Assay system (Promega, Cat# N1130) on GloMax Luminometer (Promega).
RNAi sensor assay. As developed previously66, the RNAi sensor assay AF5-V5-C,
AF5-V5-AC, and AF5-V5-eGFP (as control) cells were seeded at 2.5 × 105 cells/
well in 24-well plates and allowed to settle overnight. Cells were then co-transfected
with FFLuc-expressing pIZ-Fluc and Renilla luciferase-expressing transfection
control (pAcIE1-Rluc) plasmids together with 1 ng dsRNA against FFLuc (dsFluc)
or dsLacZ as control for dsRNA cleavage assay or 1 ng siRNA, siFluc or siHyg for
siRNA loading assay using 2 μL DharmaFECT 2 in Opti-MEM. After 24 hpt, cells
were lysed with 1× PLB and FFLuc/Rluc levels measured using a Dual-Luciferase
Reporter Assay System (Promega, Cat# E1969) following the manufacturer’s
protocol in a GloMax Luminometer (Promega).
Plaque assay. For virus titration, cell monolayers of A549-NPro cells at 4 × 105
cells/well in 12-well plates were infected with serially diluted (1:10) supernatant
from TER94, Rpn1, and AeUBR5 knockdown experiments with ZIKV PE243.
Dilutions were in DMEM supplemented with 2% FBS and incubated with an
overlay consisting of MEM with 4% FBS, 4% HEPES, and 1.2% Avicel under the
same conditions as mentioned before for 6 days. Infected cells were then fixed with
4% formaldehyde and stained with 0.2% toluidine blue to visualize plaques.
In silico analyses. In generating the PPI networks, only proteins identified in all
three replicates of V5-C and V5-AC samples but not in V5-eGFP control samples
were considered. UniProt IDs from the protein list were converted to stable gene
IDs in VectorBase52 (www.vectorbase.org) release 49 beta using the AaegL5.3
release and used to perform a multiple protein search in StringDB53 v.11.0 (www.
string-db.org) with a minimum required interaction score of 0.7 for each protein.
Networks were then exported to Cytoscape v.3.8.254 with IP proteomics interac-
tions in gray and StringDB PPI edges in cyan. Interactor nodes are labeled with
VectorBase IDs with the mean number of peptides identified and mean LFQ
intensity indicated by the size and color, respectively.
All protein interactors used in constructing the PPI network were subjected to
GO and pathway enrichment analysis. This was done by performing a database
search for gene function in VectorBase and DAVID55 v.6.8 (https://david.ncifcrf.
gov/) using the VectorBase IDs of each protein. GO terms and KEGG IDs with a p-
value of <0.05 level of significance with Benjamini correction were considered for
the analysis.
To determine D. melanogaster orthologs of interactors, OrthoDB56 v.10.1
(www.orthodb.org) was used. From D. melanogaster orthologs, human orthologs
were identified from FlyBase57 FB2020_05 release and confirmed in HGNC58
(www.genenames.org). If no ortholog was identified, a homology-based approach
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was employed using BLASTP limited to the D. melanogaster (taxid: 7227) and H.
sapiens (taxid: 9606) on NCBI (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Only
proteins with a high confidence score and similarity were considered. A
corresponding PPI network of selected drosophila or human orthologs was
constructed in StringDB and visualized in Cytoscape.
Data mining of VCP co-factors was performed in BioGRID59 v.4.2 (www.
thebiogrid.org). A total of 953 unique interactors of VCP was identified. This
dataset was compared to the human orthologs of our mosquito interactors data.
The overlap between the datasets was 32 proteins. GO analysis in DAVID and
VectorBase was performed in this subset of proteins across orthologs. Proteins
involved in ubiquitination were assessed by constructing ortholog mapping and
PPI networks. Two candidate co-factors, SQSTM1 and UBR5 were further
characterized in mosquito and A549 cells.
Data and statistical analyses. For ZIKV-NLuc infections, all NLuc readings are
presented as relative light units to corresponding NLuc readings of controls set to 1.
For dual-luciferase readings, luciferase readings were set as ratios to the luciferase
readings of its transfection control and presented as relative light units to ratio
luciferase readings of its controls set to 1. Densitometry analysis of bands detected
from cycloheximide chase assay immunoblots are presented as a relative signal of
the protein of interest to the signal of its corresponding housekeeping protein and
the ratio presented relative to the 0 h timepoint set to 1. For siRNA knockdown
efficiency immunoblots, densitometry analyses of bands are presented as a relative
signal of the target protein to the signal of its corresponding housekeeping protein
and the ratio shown relative to the siRNA negative control set to 1. For RT-qPCR
results, CT values were transformed into fold change values using the 2−ΔΔCT
method118 with S7 and GAPDH internal control genes for mosquito and A549
cells, respectively with error propagation for SDs performed across CT values. Data
were obtained from triplicate independent biological experiments, unless specified,
with at least three technical repeats per experiment and are presented as mean ±
SEM with statistical significance computed using a two-tailed Student’s t-test or
two-way ANOVA when appropriate with the level of significance set at 0.05 or 0.01
with means compared to controls or within specific timepoints to controls. All
statistical analyses and data visualizations were done in GraphPad Prism v.7. All
values, exact p-values, and uncropped immunoblots are provided in the Source
Data file.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Mass spectrometry RAW files have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository with the dataset identifier PXD020565). Supplemental
and experimental data can be accessed through the University of Glasgow Enlighten
(https://doi.org/10.5525/gla.researchdata.1020). ZIKV PE243 sequence available from
NCBI GenBank (ZIKV/H.sapiens/Brazil/PE243/2015; GenBank: KX197192.1). Ae.
aegypti mRNA sequences from NCBI RefSeq AaegL5.0 (https://www.ncbi.nlm.nih.gov/
assembly/GCF_002204515.2). Publicly available data used in particular analyses were
obtained from UniProt117 (Ae. aegypti proteome UP000008820; www.uniprot.org),
VectorBase52(AaegL5.3; www.vectorbase.org), StringDB53 (v11.0; www.string-db.org),
DAVID55 (v6.8; https://david.ncifcrf.gov/), OrthoDB56 (v10.1; www.orthodb.org),
FlyBase57 (FB2020_05; www.flybase.org), HGNC58 (www.genenames.org), and
BioGRID59 (v4.2; https://thebiogrid.org/113258/summary/homo-sapiens/vcp.html).
Further information and reagent requests including generated unique cell lines and
plasmids should be addressed to Alain Kohl, alain.kohl@glasgow.ac.uk. Source data are
provided with this paper as Source Data file.
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